Intellia Therapeutics is trading 5.4% up at $12.13, primarily linked to broader biotechnology strength; no new company-specific announcement was identified on September 17, 2026.
- XBI rose 2.55% during regular trading, alongside a wider market rebound.
- Recent FDA priority-review news for lonvo-z remains supportive background, but was announced September 8, not September 17.